Floatz logo

Ap-Pa02

Pseudomonas Aeruginosa Infectious Disease

Armata Pharmaceuticals, Inc.UNKNOWNPhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pseudomonas Aeruginosa Infectious Disease cohort.

Asset / SponsorPhaseRating
Aztreonam Lysine
Gilead Sciences
Phase 3BB
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Ceftolozane
Sunshine Coast Hospital and Health Service
Phase 4BB
Tazobactam
Sunshine Coast Hospital and Health Service
Phase 4BB
Pseudomonas Aeruginosa-Specific Bacteriophage Mixture, Live Consisting Of 3 Bacteriophages (Ihma-2121771-1, Ihma-2121771-2, Ihma-2121908-1)
BiomX Ltd
Phase 2BB

View all 12 →

Same molecule, other indications

Ap-Pa02 is also rated in:

pneumoniaActive
BB
Indicative · Phase 2
69 / 100
View asset →
bronchiectasisActive
B
Indicative · Phase 2
57 / 100
View asset →
Pseudomonas infectionDormant
CCC
Indicative · Phase 1/2
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →